Cyril Kuriakose, MD
Nephrology · Tualatin, ORNPI 1255536181
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Vifor Pharma, Inc. accounts for 81.1% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $27,428 and has fallen 99.4% since, to $152 in 2025. Among nephrology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 145 payments — averaging $245.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$29K
- Veloxis Pharmaceuticals, Inc.$5K
- BD$375
- AstraZeneca$265
- Amgen$192
- Mallinckrodt Enterprises LLC$130
- plus $1K from 22 others
What the payments were for
- Consulting fees$7,37521%
- Speaking & faculty fees$20,07056%
- Travel & lodging$4,68113%
- Food & beverage$3,45310%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 62 | $28,893 |
| Veloxis Pharmaceuticals, Inc. | 12 | $4,705 |
| BD | 1 | $375 |
| AstraZeneca(2 entities) | 8 | $265 |
| Amgen(2 entities) | 5 | $192 |
| Mallinckrodt Enterprises LLC | 5 | $130 |
| Mallinckrodt Hospital Products Inc. | 6 | $129 |
| Otsuka America Pharmaceutical, Inc. | 5 | $113 |
| Calliditas Therapeutics US Inc. | 6 | $112 |
| Novartis | 5 | $111 |
| OPKO Pharmaceuticals, LLC | 4 | $80 |
| Akebia Therapeutics Inc | 3 | $65 |
| Octapharma USA, Inc. | 3 | $46 |
| Fresenius USA Marketing, Inc. | 2 | $42 |
| Recordati_rare_diseases_inc. | 2 | $41 |
| Bayer | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Nuwellis, Inc. | 2 | $28 |
| Travere Therapeutics, Inc. | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| GSK | 1 | $23 |
| Cycle Pharmaceuticals Inc | 1 | $21 |
| Baxter Healthcare | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| EUSA Pharma (US) LLC | 1 | $21 |
| Aurinia Pharma U.S., Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,607 in reported general payments places this provider in the 95th percentile of 120 nephrology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 15 | $23,191 |
| FarxigaDapagliflozin Propanediol | 21 | $17,708 |
| InvokanaCanagliflozin | 12 | $7,071 |
| Levothyroxine Sodium | 13 | $755 |
| Carvedilol | 30 | $518 |
| Nifedipine ErNifedipine | 18 | $491 |
| Amlodipine Besylate | 59 | $471 |
| Furosemide | 66 | $434 |
| Torsemide | 13 | $429 |
| Calcitriol | 25 | $418 |
| Magnesium Sulfate | 19 | $414 |
| Hydralazine Hcl | 37 | $407 |
| Metoprolol Succinate | 29 | $332 |
| Allopurinol | 40 | $327 |
| Losartan Potassium | 55 | $312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $265 | $17,70821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 120 nephrology providers in Oregon.
Other nephrology in Tualatin
- Sanjay NeupaneTualatin$259
- Neil KumarRoseburg$532K
- Robert ProvenzanoPortland$45K
- Nayan AroraPortland$23K
- Shalin SanghviSpringfield$20K
- Ramesh MarahattaSpringfield$19K
- Rupali AvasarePortland$16K
- David EllisonPortland$12K
- Shehzad RehmanPortland$10K
- Michael FeldmanBend$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.